BridgeMD
New treatment option for Alcohol Dependence
Official title Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence
ClinicalTrials.gov ID: NCT07388693
What this study is testing
- What it's testing
- Alcohol dependence (AD) is a prevalent and burdensome clinical condition with high relapse rates. A central risk factor for relapse is craving for alcohol, which can be evoked by both real-world and virtual cues in immersive Virtual Reality (VR).
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- age: 18-65 years
- diagnosis of alcohol dependence according to ICD-10 (F10.2)
- history of alcohol craving
- able to provide written informed consent
You likely can't join if
- hyposmia
- dependence on substances other than alcohol and nicotine
- current alcohol intoxication (randomly tested by measurement of breath alcohol concentration)
- unable to understand the study information, consent form or principles of the study
- abstinence for less than 7 days or ongoing consumption of alcohol
- severe neuropsychiatric disorder (e.g. schizophrenia spectrum disorders, bipolar affective disorder) or substantial cognitive impairment
See the full eligibility criteria
- age: 18-65 years
- diagnosis of alcohol dependence according to ICD-10 (F10.2)
- history of alcohol craving
- able to provide written informed consent
- hyposmia
- dependence on substances other than alcohol and nicotine
- current alcohol intoxication (randomly tested by measurement of breath alcohol concentration)
- unable to understand the study information, consent form or principles of the study
- abstinence for less than 7 days or ongoing consumption of alcohol
- severe neuropsychiatric disorder (e.g. schizophrenia spectrum disorders, bipolar affective disorder) or substantial cognitive impairment
- serious illnesses affecting brain or heart function that influence physiological study parameters
- acute suicidality (or acute endangerment of others)
- concurrent pharmacological treatment targeting AUD (e.g. benzodiazepines) or craving (e.g. acamprosate, disulfiram, naltrexone, nalmefene) and further medication significantly influencing heart rate
The study team makes the final eligibility decision.
Where it's taking place
- Berlin, State of Berlin, Germany
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Berlin, State of Berlin, Germany. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.